A registration trial of CPI-444 in late-stage advanced refractory renal cancer patients.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 05 Nov 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Oct 2020 According to a Corvus Pharmaceuticals media release, the proposed pivotal trial will utilize the Company's Adenosine Gene Signature biomarker to select patients who may be most likely to benefit from treatment with ciforadenant plus atezolizumab.
05 Oct 2020 According to a Corvus Pharmaceuticals media release, Corvus is planning to meet with the U.S. Food & Drug Administration (FDA) in December 2020 to discuss the study design and plans for a pivotal ciforadenant study in advanced refractory renal cell cancer (RCC) using the Adenosine Gene Signature as a biomarker.
11 Nov 2017 According to a Corvus Pharmaceuticals media release, this trial is expected to begin in 2018.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com